Aphria’s Australian-based partner Althea granted Manufacture Licence by the Australian Government’s Office of Drug Control.
Health Canada approval for next phase of vaporized cannabinoid drug clinical trial.
Clinical trial to start and finish by year end
Tetra’s PPP001 is currently in Phase 3, with the end goal being a DIN,” says Aphria CEO.
“Enormous opportunity” for relationship with Tetra, as supplier and shareholder.
Aphria and Canadian bio-technology company Rapid Dose Therapeutics have signed an MOU that Aphria will have exclusive global preferred rights to produce, distribute and sell QuickStrip(TM) products for cannabis markets around the world, once a definitive agreement is signed between the two companies in the near future.